Athena Bioscience
- Company typePrivate
- Founded-
- HeadquartersWatkinsville, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Athena Bioscience firmographics
Firmographics- Name
- Athena Bioscience
- Legal name
- Athena Bioscience, LLC
- Website
- https://athenabioscience.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Athena Bioscience industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Athena Bioscience is headquartered
LocationHeadquarters
- HQ city
- Watkinsville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Athena Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Operations, Personnel, Others
Revenue model
- Pharmaceutical Product Sales: Athena Bioscience generates revenue through the sale of specialty pharmaceutical products including Nexiclon XR (clonidine extended-release tablets for hypertension), QDOLO, and FIBRICOR. The company operates as a specialty pharma focused on optimizing proven pharmaceutical therapies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Athena Bioscience product offering
Product offeringCore offering
Athena Bioscience is a specialty pharmaceutical company that develops, markets, and distributes branded prescription medications focused on optimizing proven pharmaceutical therapies. Its lead product, Nexiclon XR, is a once-daily clonidine extended-release tablet indicated for the treatment of hypertension. The company also markets additional branded pharmaceutical products including QDOLO and FIBRICOR.
Product overview
Athena Bioscience is a specialty pharmaceutical company offering a focused portfolio of branded medications. The primary product is Nexiclon™ XR, a once-daily clonidine extended-release tablet for hypertension treatment. The company's cardiovascular product portfolio is promoted through Sabal Therapeutics. The company operates affiliated websites including QDOLO.com and FIBRICOR.com, though detailed product information for those brands is not publicly available. The company focuses on optimizing proven pharmaceutical therapies to address unmet medical needs.
Differentiator
Problem solved
Functional benefit
Products and services
- Nexiclon XR Once-daily clonidine extended-release tablet indicated for the treatment of hypertension, marketed to healthcare providers and pharmacies.
- QDOLO Branded pharmaceutical product in Athena Bioscience's portfolio, distributed alongside its other specialty medications.
- FIBRICOR Branded pharmaceutical product in Athena Bioscience's portfolio of marketed medications.
Companies that use Athena Bioscience
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Athena Bioscience technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Athena Bioscience partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Sabal TherapeuticscoreSabal Therapeutics was engaged by Athena Bioscience to promote their cardiovascular product portfolio. This partnership was announced in February 2022 and covers the promotion of products including Nexiclon XR, representing a key channel distribution arrangement for cardiovascular medications.
Scale indicators1 record
Recent moves4 records
Expansion highlights4 records
Athena Bioscience competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Customer concentration
Athena Bioscience social profiles
Digital presenceAthena Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Athena Bioscience leadership team
Management profileNumber of profiles
Profiles1 record
Athena Bioscience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Athena Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Athena Bioscience
What does Athena Bioscience do?
Athena Bioscience is a specialty pharmaceutical company that develops, markets, and distributes branded prescription medications focused on optimizing proven pharmaceutical therapies. Its lead product, Nexiclon XR, is a once-daily clonidine extended-release tablet indicated for the treatment of hypertension. The company also markets additional branded pharmaceutical products including QDOLO and FIBRICOR.
Is Athena Bioscience a public or private company?
Athena Bioscience is a private company. It is classified as unknown and is currently operating.
When was Athena Bioscience founded?
Athena Bioscience was founded in -1. It employs 1 to 10 people.
Where is Athena Bioscience based?
Athena Bioscience is headquartered in Watkinsville, United States, in the North America region.
How does Athena Bioscience make money?
One revenue line is on record: pharmaceutical Product Sales.
Does Athena Bioscience have an API?
No public API is recorded for Athena Bioscience.
What industry is Athena Bioscience in?
Athena Bioscience's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.